PriceTargets.com logo

Neuphoria Therapeutics - NEUP Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $21.00
  • Forecasted Upside: 439.85%
  • Number of Analysts: 4
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.89 As of 12/18/2025 05:00 PM ET
▲ +0.09 (2.37%)

This chart shows the closing price for NEUP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neuphoria Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NEUP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NEUP

Analyst Price Target is $21.00
▲ +439.85% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Neuphoria Therapeutics in the last 3 months. The average price target is $21.00, with a high forecast of $35.00 and a low forecast of $7.00. The average price target represents a 439.85% upside from the last price of $3.89.

This chart shows the closing price for NEUP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Neuphoria Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/17/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
12/17/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/8/2025Zacks ResearchDowngradeHold ➝ Strong Sell
12/5/2025HC WainwrightLower TargetBuy ➝ Buy$21.00 ➝ $7.00
10/8/2025Weiss RatingsDowngradeHold (C-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
9/11/2025Maxim GroupBoost TargetBuy ➝ Buy$18.00 ➝ $35.00
8/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$21.00
2/4/2025HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $21.00
(Data available from 12/18/2020 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2025
  • 4 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
11/18/2025
  • 1 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2025

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Neuphoria Therapeutics logo
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Read More

Today's Range

Now: $3.89
Low: $3.85
High: $4.15

50 Day Range

MA: $6.39
Low: $3.80
High: $19.00

52 Week Range

Now: $3.89
Low: $2.77
High: $21.40

Volume

67,822 shs

Average Volume

572,937 shs

Market Capitalization

$20.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Neuphoria Therapeutics?

The following equities research analysts have issued stock ratings on Neuphoria Therapeutics in the last year: HC Wainwright, Maxim Group, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for NEUP.

What is the current price target for Neuphoria Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Neuphoria Therapeutics in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 439.8%. Maxim Group has the highest price target set, predicting NEUP will reach $35.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Neuphoria Therapeutics in the next year.
View the latest price targets for NEUP.

What is the current consensus analyst rating for Neuphoria Therapeutics?

Neuphoria Therapeutics currently has 2 sell ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NEUP, but not buy more shares or sell existing shares.
View the latest ratings for NEUP.

What other companies compete with Neuphoria Therapeutics?

Other companies that are similar to Neuphoria Therapeutics include Vaxart, BioHarvest Sciences, BeyondSpring, Leap Therapeutics and Tharimmune. Learn More about companies similar to Neuphoria Therapeutics.

How do I contact Neuphoria Therapeutics' investor relations team?

Neuphoria Therapeutics' physical mailing address is 200 GREENHILL ROAD, EASTWOOD SA C3, 5063. The company's listed phone number is 61-8-8150-7400 and its investor relations email address is [email protected]. The official website for Neuphoria Therapeutics is www.bionomics.com.au. Learn More about contacing Neuphoria Therapeutics investor relations.